Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?

DeLeonardis K, Hogan L, Cannistra SA, Rangachari D, Tung N.

J Oncol Pract. 2019 Sep;15(9):465-473. doi: 10.1200/JOP.19.00201.

PMID:
31509718
2.

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.

Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ.

Cancer Discov. 2019 Aug 15. doi: 10.1158/2159-8290.CD-19-0582. [Epub ahead of print]

PMID:
31416802
3.

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.

Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB.

J Thorac Oncol. 2019 Aug 1. pii: S1556-0864(19)30599-4. doi: 10.1016/j.jtho.2019.07.016. [Epub ahead of print]

PMID:
31377341
4.

From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

Rangachari D, Costa DB.

J Clin Oncol. 2019 Jun 2:JCO1901207. doi: 10.1200/JCO.19.01207. [Epub ahead of print] No abstract available.

PMID:
31154918
5.

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature.

Petri CR, Patell R, Batalini F, Rangachari D, Hallowell RW.

Respir Med Case Rep. 2019 Apr 6;27:100834. doi: 10.1016/j.rmcr.2019.100834. eCollection 2019.

6.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE.

Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.

PMID:
30790338
7.

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.

Varkaris A, Sehgal K, Rangachari D, Costa DB.

J Thorac Oncol. 2019 Feb;14(2):e34-e36. doi: 10.1016/j.jtho.2018.10.157. No abstract available.

PMID:
30683297
8.

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.

Sehgal K, Patell R, Rangachari D, Costa DB.

Transl Cancer Res. 2018 Aug;7(Suppl 7):S779-S786. doi: 10.21037/tcr.2018.08.11. No abstract available.

9.

Lung Cancer with a High Tumor Mutational Burden.

VanderLaan PA, Rangachari D, Costa DB.

N Engl J Med. 2018 Sep 13;379(11):1093. doi: 10.1056/NEJMc1808566. No abstract available.

PMID:
30211492
10.

Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.

Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA.

Cancer Treat Res Commun. 2018;15:17-20. doi: 10.1016/j.ctarc.2018.02.004. Epub 2018 Feb 21.

PMID:
30207283
11.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB.

Clin Cancer Res. 2018 Dec 15;24(24):6548-6555. doi: 10.1158/1078-0432.CCR-18-1541. Epub 2018 Aug 28.

PMID:
30154228
12.

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.

Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB.

J Thorac Oncol. 2019 Jan;14(1):e1-e3. doi: 10.1016/j.jtho.2018.06.020. Epub 2018 Jul 5. No abstract available.

PMID:
29981924
13.

Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.

VanderLaan PA, Chen Y, DiStasio M, Rangachari D, Costa DB, Heher YK.

Clin Lung Cancer. 2018 Sep;19(5):e589-e590. doi: 10.1016/j.cllc.2018.04.005. Epub 2018 May 4. No abstract available.

PMID:
29798809
14.

PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA.

J Am Soc Cytopathol. 2018 May-Jun;7(3):133-141. doi: 10.1016/j.jasc.2018.02.003. Epub 2018 Feb 16.

15.

Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.

Rangachari D, VanderLaan PA, Costa DB.

J Thorac Oncol. 2018 May;13(5):e81-e83. doi: 10.1016/j.jtho.2018.01.023. No abstract available.

16.

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM.

J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6.

17.

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2018 Feb;116:90-95. doi: 10.1016/j.lungcan.2018.01.002. Epub 2018 Jan 4.

18.

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

Le X, Rangachari D, Costa DB.

J Thorac Dis. 2017 Sep;9(9):2812-2818. doi: 10.21037/jtd.2017.08.79. No abstract available.

19.

Beyond the Sandwich: From Feedback to Clinical Coaching for Residents as Teachers.

Brown LE, Rangachari D, Melia M.

MedEdPORTAL. 2017 Sep 18;13:10627. doi: 10.15766/mep_2374-8265.10627.

20.

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

Carney BJ, Rangachari D, VanderLaan PA, Gowen K, Schrock AB, Ali SM, Costa DB.

Lung Cancer. 2017 Dec;114:108-110. doi: 10.1016/j.lungcan.2017.08.018. Epub 2017 Aug 24. No abstract available.

PMID:
28870636
21.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 Nov;12(11):e175-e177. doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10. No abstract available.

22.

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.

DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA.

Clin Lung Cancer. 2017 Sep;18(5):e349-e356. doi: 10.1016/j.cllc.2017.03.001. Epub 2017 Mar 14.

PMID:
28377205
23.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.

Peters MLB, Costa DB, Rangachari D.

J Thorac Oncol. 2017 Apr;12(4):e35-e36. doi: 10.1016/j.jtho.2016.12.018. No abstract available.

24.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB.

Lung Cancer. 2017 Apr;106:17-21. doi: 10.1016/j.lungcan.2017.01.011. Epub 2017 Jan 25.

25.

Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease.

Rangachari D, Costa DB.

Transl Cancer Res. 2017 Feb;6(Suppl 1):S151-S157. doi: 10.21037/tcr.2017.02.28. No abstract available.

26.

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB.

Cancer Treat Commun. 2016;9:41-43. doi: 10.1016/j.ctarc.2016.07.001. Epub 2016 Jul 5.

27.

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.

Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16.

28.

Clinical coaching: Evolving the apprenticeship model for modern housestaff.

Rangachari D, Brown LE, Kern DE, Melia MT.

Med Teach. 2017 Jul;39(7):780-782. doi: 10.1080/0142159X.2016.1270425. Epub 2016 Dec 26.

PMID:
28024461
29.

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB.

Clin Lung Cancer. 2016 Nov;17(6):483-492. doi: 10.1016/j.cllc.2016.05.016. Epub 2016 Jun 8. Review.

PMID:
27381270
30.

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2016 Sep;99:17-22. doi: 10.1016/j.lungcan.2016.06.006. Epub 2016 Jun 14.

31.

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB.

Lung Cancer. 2015 Dec;90(3):369-74. doi: 10.1016/j.lungcan.2015.10.028. Epub 2015 Oct 31.

32.

Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship.

Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R.

J Cancer Educ. 2017 Sep;32(3):496-502. doi: 10.1007/s13187-015-0974-1.

PMID:
26768145
33.

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Shea M, Costa DB, Rangachari D.

Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30. Review.

34.

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.

Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB.

Cancer Treat Commun. 2015;4:174-181.

35.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB.

Clin Lung Cancer. 2015 Sep;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. Epub 2015 Mar 25. No abstract available.

36.

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.

Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB.

Lung Cancer. 2015 Apr;88(1):70-3. doi: 10.1016/j.lungcan.2015.02.003. Epub 2015 Feb 7.

37.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB.

Lung Cancer. 2015 Apr;88(1):108-11. doi: 10.1016/j.lungcan.2015.01.020. Epub 2015 Feb 4.

38.

Quiz page January 2014: Cachexia, urinary tract infection, nephromegaly, and kidney failure.

Storm A, Bhasin B, Rangachari D, Sperati CJ.

Am J Kidney Dis. 2014 Jan;63(1):A18-21. doi: 10.1053/j.ajkd.2013.07.027. No abstract available.

PMID:
24360229
39.

Integrating palliative care in oncology: the oncologist as a primary palliative care provider.

Rangachari D, Smith TJ.

Cancer J. 2013 Sep-Oct;19(5):373-8. doi: 10.1097/PPO.0b013e3182a76b9c. Review.

40.

Targeting the immune system in the treatment of non-small-cell lung cancer.

Rangachari D, Brahmer JR.

Curr Treat Options Oncol. 2013 Dec;14(4):580-94. doi: 10.1007/s11864-013-0250-8. Review.

PMID:
23934510
41.

Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival.

Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL, Meneshian A, Yang SC, Wolfgang CL.

J Gastrointest Surg. 2011 Sep;15(9):1611-7. doi: 10.1007/s11605-011-1605-8. Epub 2011 Jul 2.

Supplemental Content

Loading ...
Support Center